Utah Medical's Q2 revenue falls on lower PendoTECH sales

Utah Medical Products

24/07/2025 14:10

Overview

Utah Medical Q2 2025 revenue falls 4.3% yr/yr, driven by lower PendoTECH sales

Company's gross profit margin contracts due to lower sales, unfavorable product mix

Share repurchases help mitigate EPS decline despite revenue and profit challenges

Outlook

Company expects 2H 2025 PendoTECH sales to be $200 lower than 2H 2024

Utah Medical projects 2025 sales to PendoTECH $2 mln lower than 2024

Result Drivers

PENDOTECH SALES DECLINE - Major driver of revenue drop with sales $315 lower in Q2 2025 compared to Q2 2024

UNFAVORABLE PRODUCT MIX - Gross profit margin contracted due to lower sales and product mix issues in Ireland

LITIGATION COST REDUCTION - Operating income decline was less severe due to $355 lower litigation costs in Q2 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
$9.95 mln
Q2 EPS
$0.94
Q2 Net Income
$3.05 mln
Q2 Gross Profit
$5.60 mln
Q2 Operating Income
$3.20 mln
Q2 Pretax Profit
$3.84 mln


Press Release: ID:nACSxzpHca

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)